MCID: PRM127
MIFTS: 37

Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Categories: Blood diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MalaCards integrated aliases for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:

Name: Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type 58 17
Pcdlbcl,lt 58

Classifications:

Orphanet: 58  
Rare skin diseases
Rare haematological diseases


External Ids:

ICD10 via Orphanet 33 C83.3
Orphanet 58 ORPHA178544

Summaries for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MalaCards based summary : Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, also known as pcdlbcl,lt, is related to marginal zone b-cell lymphoma and diffuse large b-cell lymphoma. An important gene associated with Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type is IRF4 (Interferon Regulatory Factor 4), and among its related pathways/superpathways are T cell receptor signaling pathway and Apoptosis Modulation and Signaling. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include liver, bone and endothelial, and related phenotypes are cellular and hematopoietic system

Related Diseases for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Diseases related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Related Disease Score Top Affiliating Genes
1 marginal zone b-cell lymphoma 30.6 MYD88 IRF4
2 diffuse large b-cell lymphoma 30.6 MYD88 MYC IRF4 CDKN2A CD274
3 b-cell lymphoma 30.6 MYD88 MYC IRF4 CDKN2A CD274
4 lymphoma 30.4 MYD88 MYC IRF4 CDKN2A CD274
5 testicular lymphoma 29.9 PDCD1LG2 MYD88 IRF4 CD274
6 mantle cell lymphoma 29.8 MYC CDKN2A CD274
7 primary cutaneous b-cell lymphoma 10.6
8 rheumatoid arthritis 10.5
9 arthritis 10.5
10 primary cutaneous follicle center lymphoma 10.5
11 primary cutaneous lymphoma 10.5
12 immune deficiency disease 10.3
13 human herpesvirus 8 10.3
14 cutaneous t cell lymphoma 10.3
15 hereditary lymphedema i 10.3
16 lymphoblastic lymphoma 10.3
17 ureteral benign neoplasm 10.3
18 polyneuropathy 10.3
19 poems syndrome 10.3
20 sporotrichosis 10.3
21 urticaria 10.3
22 cellulitis 10.3
23 skin disease 10.3
24 hist1h1e syndrome 10.3
25 lymphomatoid granulomatosis 10.3
26 soft tissue sarcoma 10.3
27 encephalopathy 10.3
28 epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly 10.3
29 waldenstroem's macroglobulinemia 10.1 MYD88 IRF4
30 myeloid sarcoma 10.1 IRF4 CD274
31 gray zone lymphoma 10.0 PDCD1LG2 CD274
32 autoimmune cardiomyopathy 10.0 PDCD1LG2 CD274
33 type 1 diabetes mellitus 21 10.0 PDCD1LG2 CD274
34 lung non-squamous non-small cell carcinoma 10.0 PDCD1LG2 CD274
35 gastroesophageal junction adenocarcinoma 10.0 PDCD1LG2 CD274
36 anogenital venereal wart 10.0 MYD88 CDKN2A
37 myopathy, distal, 1 10.0 PDCD1LG2 CD274
38 epstein-barr virus-associated gastric carcinoma 10.0 CDKN2A CD274
39 bladder squamous cell carcinoma 10.0 CDKN2A CD274
40 vulva squamous cell carcinoma 10.0 CDKN2A CD274
41 malignant spindle cell melanoma 10.0 CDKN2A CD274
42 vulvar disease 10.0 CDKN2A CD274
43 anus cancer 10.0 CDKN2A CD274
44 acral lentiginous melanoma 10.0 CDKN2A CD274
45 pediatric lymphoma 10.0 MYC IRF4
46 adult lymphoma 10.0 MYC IRF4
47 angioimmunoblastic t-cell lymphoma 9.9 PDCD1LG2 CD274
48 intravascular large b-cell lymphoma 9.9 MYD88 MYC
49 follicular dendritic cell sarcoma 9.9 CDKN2A CD274
50 richter's syndrome 9.9 MYC IRF4

Graphical network of the top 20 diseases related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:



Diseases related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Symptoms & Phenotypes for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MGI Mouse Phenotypes related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.85 ATF6 CD274 CDKN2A IRF4 MYC MYD88
2 hematopoietic system MP:0005397 9.8 CD274 CDKN2A IRF4 MYC MYD88 PDCD1LG2
3 homeostasis/metabolism MP:0005376 9.8 ATF6 CD274 CDKN2A IRF4 MYC MYD88
4 immune system MP:0005387 9.63 CD274 CDKN2A IRF4 MYC MYD88 PDCD1LG2
5 neoplasm MP:0002006 9.35 CDKN2A IRF4 MYC MYD88 PDCD1LG2
6 no phenotypic analysis MP:0003012 9.1 ATF6 CD274 CDKN2A MYC MYD88 PDCD1LG2

Drugs & Therapeutics for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Drugs for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
2
Racepinephrine Approved Phase 4 329-65-7 838
3
Bromhexine Approved Phase 4 3572-43-8
4
Simethicone Approved Phase 4 8050-81-5
5
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
6
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
7
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
8
tannic acid Approved Phase 4 1401-55-4
9
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
10
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
11
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
12
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
13
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
14
Mycophenolic acid Approved Phase 4 24280-93-1 446541
15
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
16
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
17
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
18
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
19 Cola Phase 4
20 Calamus Phase 4
21 Epinephryl borate Phase 4
22 Methylprednisolone Acetate Phase 4
23 Triamcinolone diacetate Phase 4
24 Triamcinolone hexacetonide Phase 4
25 triamcinolone acetonide Phase 4
26
Metformin Approved Phase 3 657-24-9 4091 14219
27
Saxagliptin Approved Phase 3 361442-04-8 11243969
28
Glyburide Approved Phase 3 10238-21-8 3488
29
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
30
Pioglitazone Approved, Investigational Phase 3 111025-46-8 4829
31
Abatacept Approved Phase 3 332348-12-6 10237
32
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
33
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
34
Naproxen Approved, Vet_approved Phase 2, Phase 3 22204-53-1 1302 156391
35
Busulfan Approved, Investigational Phase 3 55-98-1 2478
36
Dopamine Approved Phase 3 62-31-7, 51-61-6 681
37
Aripiprazole Approved, Investigational Phase 3 129722-12-9 60795
38
Aldesleukin Approved Phase 3 85898-30-2, 110942-02-4
39
Ambrisentan Approved, Investigational Phase 3 177036-94-1 6918493
40
Sirolimus Approved, Investigational Phase 3 53123-88-9 6436030 5284616
41
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
42
Etoposide Approved Phase 3 33419-42-0 36462
43
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
44
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
45
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
46
leucovorin Approved Phase 3 58-05-9 6006
47
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
48
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
49
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
50
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516

Interventional clinical trials:

(show top 50) (show all 133)
# Name Status NCT ID Phase Drugs
1 Home Oxygen Therapy in the Ambulatory Treatment of Bronchiolitis Unknown status NCT01216553 Phase 4
2 SMALL BOWEL CLEANSING FOR CAPSULE ENDOSCOPY IN PEDIATRIC PATIENTS: A PROSPECTIVE RANDOMIZED SINGLE-BLINDED STUDY Unknown status NCT01783782 Phase 4 polyethylene glycol 4000 solution with simethicon;simethicon
3 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
4 A Study in Adults on Pre LT Dialysis With Basiliximab, Delayed Tacrolimus (TAC), Mycophenolate (MMF), Steroids (Grp 1) vs. Basiliximab, Delayed TAC, MMF, Steroids, With Everolimus 30d Post LT(Grp 2), vs. TAC, MMF, Steroids (Grp 3). Not yet recruiting NCT04104438 Phase 4 Basiliximab 20 MG
5 Prehospital Laryngeal Tube vs. Bag-Valve Mask Ventilation Used by Paramedics During CPR- A Prospective, Controlled, Randomised, Multi-center Trial Terminated NCT01718795 Phase 4
6 Use of New Supraglottic Airway Devices in Severely Obese Patients: A Feasibility Study Withdrawn NCT01124825 Phase 4
7 Multicenter Randomized Controlled Trial of Adenovirus-mediated Adjuvant Gene Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma Unknown status NCT03313596 Phase 3 ADV-Tk
8 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise Completed NCT00121641 Phase 3 Saxagliptin;Saxagliptin;Saxagliptin;Placebo matching Saxagliptin;Metformin;Placebo matching Metformin;Saxagliptin;Metformin
9 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise Completed NCT00316082 Phase 3 Saxagliptin;Saxagliptin;Saxagliptin;Saxagliptin;Placebo;metformin
10 A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Glyburide in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Glyburide Alone Completed NCT00313313 Phase 3 Saxagliptin;Saxagliptin;Glyburide;Placebo;Glyburide;Metformin
11 A Multicenter, Randomized, Double Blind, Placebo Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS477118) in Combination With Thiazolidinedione Therapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Thiazolidinedione Therapy Alone Completed NCT00295633 Phase 3 Saxagliptin;Saxagliptin;Placebo;pioglitazone;rosiglitazone;metformin
12 A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control Completed NCT00327015 Phase 3 Saxagliptin;Saxagliptin;Metformin;Placebo;pioglitazone
13 "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone" Completed NCT00121667 Phase 3 Saxagliptin + Metformin;Saxagliptin + Metformin;Saxagliptin + Metformin;Placebo + Metformin;Pioglitazone
14 Mechanism of Action and Efficacy of Saxagliptin (BMS-477118) in the Treatment of Type 2 Diabetic Patients Completed NCT00374907 Phase 3 Saxagliptin;Placebo;Metformin (blinded);Metformin (open-label)
15 Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 48-weeks Treatment With Gastro-resistant Phosphatidylcholine (LT-02) Versus Placebo Versus Mesalamine for Maintenance of Remission in Patients With Ulcerative Colitis Completed NCT02280629 Phase 3 LT-02;Placebo;Mesalamine
16 Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT) Completed NCT00256750 Phase 3 Cyclosporine (CsA);Belatacept LI (less intensive);Belatacept MI (more intensive)
17 Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Developed Cooperatively by YunNan Walvax Biotechnology Co., Lt and Yuxi Walvax Biotechnology Co., Lt Among 2-71 Months (the Youngest Could be 6 Weeks) Healthy Infants and Toddlers by Randomized Blind Method With Similar Control in Multi-centers. Completed NCT02736240 Phase 3
18 Acupuncture for Dry Eye Syndrome : A Randomized, Patient-Assessor Blinded, Non-acupuncture Point Shallow Penetration-Controlled Study Completed NCT00969280 Phase 3
19 Systemic Chemotherapy, Second Look Surgery and Conformal Radiation Therapy Limited to the Posterior Fossa and Primary Site for Children >/= to 8 Months and <3 Years With Non-metastatic Medulloblastoma: A Children&Apos;s Oncology Group Phase III Study Completed NCT00006461 Phase 3 cisplatin;cyclophosphamide;vincristine sulfate;etoposide
20 A Double-Blind, Double-Dummy, Randomized, Active-Comparator, Non-Inferiority Study of LT-NS001 Versus Naprosyn® for Twelve Weeks in Osteoarthritis Patients to Compare Endoscopic Gastric Ulcer Rates Completed NCT01063920 Phase 2, Phase 3 LT-NS001;Naprosyn®
21 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode. CN138-146 LT is the 26-week Open Label Extension Phase of the Above Titled Protocol, CN138-146 ST. Completed NCT00094432 Phase 3 Aripiprazole;Placebo
22 Phase III Randomized Study of Induction Chemotherapy With or Without MDR-Modulation With PSC-833 (NSC # 648265, IND # 41121) Followed by Cytogenetic Risk-Adapted Intensification Therapy Followed by Immunotherapy With rIL-2 (NSC # 373364, IND # 1969) vs. Observation in Previously Untreated Patients With AML < 60 Years Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
23 ABS-LT: A Phase 3, Long-Term, Open Label, Multicenter Safety Study of Ambrisentan in Subjects With Pulmonary Hypertension Completed NCT00777920 Phase 3 Ambrisentan
24 Safety and Efficacy of Combined Extracorporeal CO2 Removal and Renal Replacement Therapy in Patients With the Acute Respiratory Distress Syndrome and Acute Renal Failure Completed NCT01239966 Phase 3
25 A Pilot Study to Determine the Safety and Efficacy of Induction-Therapy, De Novo MPA and Delayed mTOR-Inhibition in Liver Transplant Recipients With Impaired Renal Function. (PATRON-Study) Completed NCT00604357 Phase 3 anti-CD 25 mAb, Sirolimus, MMF
26 A Phase Three, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System Completed NCT00993681 Phase 3
27 "A Prospective, Randomized Controlled Clinical Investigation of MAVERICK™ Total Disc Replacement in Patients With Degenerative Disc Disease" Completed NCT00635843 Phase 3
28 A 3-Year, Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects With Ulcerative Colitis (UC) Recruiting NCT03920254 Phase 2, Phase 3 TD-1473 Dose A;TD-1473 Dose B;TD-1473 Dose C
29 Curative Potential of Liver Transplantation in Patients With Definitively Unresectable Colorectal Liver Metastases (CLM) Treated by Chemotherapy: a Prospective Multicentric Randomized Trial Recruiting NCT02597348 Phase 3
30 A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children <36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue Versus the Same Therapy Without Methotrexate Active, not recruiting NCT00336024 Phase 3 etoposide;cyclophosphamide;cisplatin;carboplatin;thiotepa;methotrexate;leucovorin calcium;vincristine sulfate
31 A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment With LT-02 vs. Placebo in Subjects With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine Terminated NCT02849951 Phase 3 LT-02;LT-02 Placebo
32 Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 12-weeks add-on Treatment With LT 02 vs. Placebo in Patients With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine Terminated NCT02142725 Phase 3 LT-02;LT-02;Placebo
33 Prospective Randomized Double Blind Placebo Controlled Trial of Rifaximin 550mg PO Twice Daily for Three Months to Prevent Recurrent Fibrosis in Liver Transplant Recipients With Chronic Hepatitis C Virus Infection Unknown status NCT01603108 Phase 2 Rifaximin;Placebo
34 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
35 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
36 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With B-Cell Lymphoma Unknown status NCT00007839 Phase 1, Phase 2 beta alethine
37 A Study to Investigate the Efficacy of LT-02 in Patients With Mesalazine Refractory Ulcerative Colitis Unknown status NCT01011322 Phase 2 LT-02;placebo
38 A Radomized, Double-blind, and Placebo-controlled Multicenter Clinical Trial of Hydroxytriptolide, in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Completed NCT02202395 Phase 1, Phase 2 LTS 0.25mg;LTS 0.5mg;LTS 1.0mg;Placebo
39 A Phase 2, Randomized, Open-Label Study to Compare the Immunogenicity and Safety of a Self-Administered LT Vaccine Patch With an LT Vaccine Patch Administered by a Clinician Completed NCT00565461 Phase 2
40 A Randomized Blinded, LT Dose-ranging Study to Assess the Immunogenicity and Safety of Different Doses of LT Adjuvant Patch Administered in Conjunction With Different Doses of Inactivated Influenza A/H5N1 Vaccine in Healthy Adults Completed NCT00908687 Phase 2
41 A Phase II, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection With Enterotoxigenic Escherichia Coli Occurring After Transcutaneous Immunization in a Field Setting Completed NCT00516659 Phase 2
42 A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection Completed NCT02534350 Phase 2 Presatovir;Placebo
43 Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML < 60 Years Completed NCT00416598 Phase 2 Busulfan;Cytarabine;Daunorubicin Hydrochloride;Decitabine;Etoposide
44 Randomized Double-Blinded Pilot Study Confirming A Human Challenge Model Using LSN03-016011/A Expressing LT And CS17 And Investigating The Safety Of VLA1701 (An Investigational Oral Cholera And ETEC Vaccine) Completed NCT03576183 Phase 2
45 Development of a Polyvalent Vaccine Against Enterotoxigenic Escherichia Coli (ETEC)Protective Efficacy of the Deletion-Attenuated, Multi-valent ACE527 Against Challenge With a Prototype Strain of Enterotoxigenic E.Coli Expressing LT and ST Enterotoxins and CFA/I (Strain H10407) in Human Challenge Model. Completed NCT01060748 Phase 2
46 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults Completed NCT00751777 Phase 2
47 Randomized, Double-Blinded, Placebo-Controlled, Dose Ranging Study to Assess the Immunogenicity and Safety of LT Application in Healthy Adults Completed NCT00672035 Phase 2
48 Phase 1/2 Study of Photodynamic Therapy (PDT) With Lemuteporfin Topical Solution (LTS) in Healthy Volunteers and in Subjects With Mild Acne Completed NCT01490736 Phase 1, Phase 2 Lemuteporfin
49 A Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Immunogenicity of an Oral Inactivated ETEC Vaccine (ETVAX) Alone and Together With dmLT Adjuvant in Descending Age Groups in Bangladesh Completed NCT02531802 Phase 1, Phase 2
50 A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers' Diarrhea Vaccine System in Travelers to Asia Completed NCT01040325 Phase 2

Search NIH Clinical Center for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Genetic Tests for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Anatomical Context for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

MalaCards organs/tissues related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:

40
Liver, Bone, Endothelial, Eye, Spinal Cord, Skin

Publications for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Articles related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type:

(show top 50) (show all 114)
# Title Authors PMID Year
1
A case of false identity: Primary cutaneous diffuse large B-cell lymphoma masquerading as Madura Foot. 61
33573513 2021
2
TdT-positive primary cutaneous diffuse large B-cell lymphoma, leg type phenotypically mimicking B-lymphoblastic lymphoma. 61
33403671 2021
3
Primary cutaneous diffuse large B-cell lymphoma, leg type, in a patient with rheumatoid arthritis undergoing etanercept therapy. 61
33238812 2020
4
Primary cutaneous follicle center lymphoma in a 16-year-old girl. 61
33326136 2020
5
Indolent clinical behaviour of primary cutaneous diffuse large B-cell lymphoma, leg type, with double MYC and BCL6 gene rearrangement. 61
32780869 2020
6
Two instructive cases of primary cutaneous diffuse large B-cell lymphoma (leg type) mimicking cellulitis and sporotrichosis. 61
32875027 2020
7
Cutaneous B-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. 61
32815650 2020
8
Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. 61
32238727 2020
9
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: A Case Report. 61
32566435 2020
10
Diagnosis and Treatment of Primary Cutaneous B-Cell Lymphomas: State of the Art and Perspectives. 61
32521744 2020
11
18FDG PET/CT in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. 61
32209875 2020
12
A case of a primary cutaneous diffuse large B-cell lymphoma, leg type. 61
31884690 2020
13
Challenges in Assessing MYC Rearrangement in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-Type. 61
31764222 2020
14
A Unique Presentation of Cutaneous Diffuse Large B-Cell Lymphoma. 61
32318298 2020
15
Diffuse large B-cell lymphoma variants: an update. 61
31735345 2020
16
Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type. 61
31566707 2019
17
Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type. 61
31150604 2019
18
Addictive response of primary cutaneous diffuse large B cell lymphoma leg type to low-dose ibrutinib. 61
31446456 2019
19
Acquired N-Linked Glycosylation Motifs in B-Cell Receptors of Primary Cutaneous B-Cell Lymphoma and the Normal B-Cell Repertoire. 61
31042459 2019
20
Primary cutaneous B-cell lymphoma: narrative review of the literature. 61
29144099 2019
21
Widespread primary cutaneous diffuse large B-cell lymphoma, leg type, with nasal involvement. 61
31099459 2019
22
A rare case of primary cutaneous diffuse large B-cell lymphoma, leg type in a patient with chronic lymphedema of the leg. 61
31361244 2019
23
Effectiveness of lenalidomide in relapsed primary cutaneous diffuse large B-cell lymphoma, leg type. 61
31110725 2019
24
Primary cutaneous diffuse large B-cell lymphoma, leg type, localized in the right periorbital region. 61
30230576 2019
25
[Primary skin lymphomas: Current therapy]. 61
30709635 2019
26
Cutaneous B-Cell Lymphoma. 61
30497672 2019
27
CD5-Positive Primary Cutaneous Diffuse Large B-Cell Lymphoma-Leg Type. 61
30792929 2019
28
High Incidence and Clinical Significance of MYC Rearrangements in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. 61
30113335 2018
29
Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management. 61
30039522 2018
30
Primary Cutaneous Follicle Center Lymphoma. 61
30407851 2018
31
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. 61
29596904 2018
32
A rare case of primary cutaneous diffuse large B-cell lymphoma, leg type. 61
30372723 2018
33
Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas. 61
29581544 2018
34
Spontaneous Regression of Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. 61
29508000 2018
35
Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy. 61
29899297 2018
36
Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response. 61
29693055 2018
37
PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. 61
29112015 2018
38
Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. 61
28543967 2017
39
Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type. 61
28838616 2017
40
Relapsed Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type. 61
29263555 2017
41
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Spontaneous Regression After Biopsy. 61
28926365 2017
42
Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing. 61
28479318 2017
43
Primary Cutaneous B-cell Lymphomas. 61
28802500 2017
44
Spontaneous regression of a primary cutaneous diffuse large B-cell lymphoma, leg type. 61
27374170 2017
45
Primary cutaneous B-cell lymphomas with large cell predominance-primary cutaneous follicle center lymphoma, diffuse large B-cell lymphoma, leg type and intravascular large B-cell lymphoma. 61
28065463 2017
46
Cutaneous lymphoma misdiagnosed as chronic lymphadenitis. 61
25903778 2016
47
Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. 61
27650702 2016
48
Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. 61
27665744 2016
49
TOX expression in cutaneous B-cell lymphomas. 61
27180090 2016
50
An 88-year-old woman with an ulcerous tumour on the leg. Primary cutaneous diffuse large-B-cell lymphoma, leg type. 61
26951356 2016

Variations for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Expression for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Search GEO for disease gene expression data for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

Pathways for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Pathways related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.09 MYD88 IRF4 CD274
2
Show member pathways
11.88 MYD88 MYC IRF4 CDKN2A
3 11.44 PDCD1LG2 MYD88 IRF4 CD274
4 11.22 PDCD1LG2 CD274
5 10.75 MYD88 ATF6
6
Show member pathways
10.6 MYC CDKN2A
7 10.5 MYC CDKN2A

GO Terms for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

Biological processes related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.81 MYC IRF4 CDKN2A ATF6
2 cell surface receptor signaling pathway GO:0007166 9.65 PDCD1LG2 MYD88 CD274
3 immune system process GO:0002376 9.62 PDCD1LG2 MYD88 IRF4 CD274
4 cytokine-mediated signaling pathway GO:0019221 9.58 MYD88 MYC IRF4
5 type I interferon signaling pathway GO:0060337 9.54 MYD88 IRF4
6 positive regulation of T cell proliferation GO:0042102 9.52 PDCD1LG2 CD274
7 T cell costimulation GO:0031295 9.49 PDCD1LG2 CD274
8 negative regulation of T cell proliferation GO:0042130 9.46 PDCD1LG2 CD274
9 negative regulation of interferon-gamma production GO:0032689 9.43 PDCD1LG2 CD274
10 positive regulation of interleukin-10 production GO:0032733 9.37 IRF4 CD274
11 defense response to protozoan GO:0042832 9.26 MYD88 IRF4
12 negative regulation of interleukin-10 production GO:0032693 9.16 PDCD1LG2 CD274
13 cellular response to lipopolysaccharide GO:0071222 9.13 PDCD1LG2 MYD88 CD274
14 negative regulation of activated T cell proliferation GO:0046007 8.62 PDCD1LG2 CD274

Molecular functions related to Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 8.8 MYC IRF4 CDKN2A

Sources for Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....